The biological efficacy of glycans is often dictated by their presentation. While individual oligosaccharides possess specific binding motifs, their physiological impact frequently relies on "multivalency", the clustering of multiple sugar moieties to enhance receptor affinity. CD BioGlyco addresses this critical need through our polymerization-based glycan modification service. As a specialized branch of our synthetic biology-based platform, this service focuses on the synthesis of high-definition glycopolymers and glycoconjugates. By grafting glycans onto synthetic or bio-based polymer backbones, we transform simple sugars into potent bioactive materials. Our approach overcomes the inherent limitations of monomeric glycans, such as rapid clearance and weak binding, by engineering macromolecular architectures that mimic the dense glycan presentation of cell surfaces. Whether for drug delivery, vaccine stabilization, or tissue engineering, we provide the chemical and biological precision necessary to "polymerize" your glycan research into preclinical reality.
Core Technologies
We employ a sophisticated toolkit of polymerization and conjugation chemistries to ensure structural control and biological activity:
Reversible Addition-Fragmentation Chain Transfer (RAFT) Polymerization
A controlled radical polymerization technique that allows for the creation of glycopolymers with precise molecular weights and narrow dispersity (low PDI).
Post-Polymerization Functionalization
Utilizing "activated ester" backbones, such as pentafluorophenyl acrylate (PFPA), to graft glycans via hydrazone or amide linkages, ensuring high density without compromising polymer integrity.
Ring-Opening Polymerization (ROP)
Ideal for creating biodegradable glyco-polypeptides or polyesters, providing a sustainable and biocompatible scaffold for therapeutic glycans.
Bio-orthogonal Click-Chemistry Grafting
Integrating azide or alkyne handles for the rapid, site-specific attachment of complex glycans to pre-formed polymer chains in aqueous environments.
Statistical and Block Co-polymerization
Engineering polymers with distinct "blocks" of glycans and other functional monomers (e.g., stimuli-responsive units) to create "smart" glyco-nanoparticles.
Amplifying Glycan Bioactivity through Precision Polymer Engineering.
The service scope of our polymerization-based glycan modification platform is designed to provide high-density, multivalent solutions for complex biological challenges. We specialize in the synthesis of glyco-mimetic polymers that replicate the spatial arrangement of glycans found on viral capsids and bacterial cell walls. This includes the development of polymeric glycan-decoys designed to competitively inhibit pathogen adhesion, a critical area in anti-viral and anti-bacterial research.
We provide comprehensive support for the creation of targeted drug delivery vehicles, where glycopolymers act as both the structural scaffold and the targeting ligand for specific lectins or cell-surface receptors. Our scope extends to the engineering of glycan-functionalized hydrogels and surfaces, utilizing "grafted-to" or "grafted-from" techniques to create biologically active interfaces for cell culture and tissue regeneration. We also offer polymeric vaccine adjuvants, where glycans are co-polymerized with immunostimulatory motifs to enhance the duration and intensity of the immune response. With capabilities ranging from custom linear glycopolymers to complex star-shaped architectures, we handle the synthesis of polymers with molecular weights from 5 kDa to over 500 kDa. Our service is inclusive of all glycan types, including sialylated oligosaccharides, glycosaminoglycans, and synthetic glyco-analogs, ensuring that your specific biological motif is presented in its most effective multivalent form.
Workflow
Macromolecular Design
Our team collaborates with you to design the optimal polymer architecture. This includes selecting the appropriate polymer backbone (linear, branched, or star-shaped), determining the target molecular weight and polydispersity index (PDI), and defining the ideal glycan valency and spatial presentation to achieve optimal multivalent binding and functional performance for your specific biological target.
Monomer Synthesis & Preparation
We provide comprehensive support for monomer preparation. This includes the chemical synthesis of custom glycomonomers, where carbohydrates are pre-functionalized with polymerizable groups (e.g., acrylates, norbornenes, or cyclic monomers for ROP), or the synthesis of reactive polymer precursors containing handles (e.g., activated esters, azides, or alkynes) for subsequent glycan conjugation.
Controlled Polymerization Execution
The polymerization is conducted using state-of-the-art controlled/living techniques such as RAFT, ATRP, or ROP. Reactions are performed under rigorously optimized conditions, with real-time monitoring (e.g., via in-line NMR or sampling for GPC analysis) to precisely control polymer chain growth, molecular weight, and dispersity, ensuring batch-to-batch reproducibility.
Glycan Grafting & Conjugation
For post-polymerization functionalization, we conjugate the desired glycan motifs onto the reactive polymer scaffold using highly efficient chemoselective reactions (e.g., click chemistry, amidation). The stoichiometry, reaction time, and catalyst are meticulously optimized to achieve the target glycan "grafting density" and maintain bioactivity, as validated by quantitative analytical methods.
Purification & Fractionation
The crude glycopolymer undergoes stringent purification to remove all synthetic impurities, including unreacted monomers, catalysts, and small-molecule byproducts. We employ techniques such as dialysis, tangential flow filtration (TFF), and preparative size-exclusion chromatography (SEC) to isolate the product with high macromolecular purity and narrow dispersity.
Advanced Characterization
Each batch is thoroughly characterized to confirm structural fidelity and performance specifications. Multi-angle light scattering coupled with GPC (GPC/SEC-MALS) provides absolute molecular weight and size distribution. Quantitative NMR spectroscopy (e.g., 1H, 19F, or 31P NMR) is used to determine the exact glycan loading (grafting density) and confirm chemical structure.
Publication Data
Journal: Biophysica
DOI: 10.3390/biophysica6020023
Published: 2026
Results: This study provides a comprehensive review of recent technological advancements in the formulation and delivery of mRNA vaccines, which are pivotal for their stability, efficacy, and global accessibility. The authors analyze the critical role of lipid nanoparticles (LNPs) as the primary delivery system, highlighting innovations in lipid design, component ratios, and ionizable cationic lipids that enhance stability, cellular uptake, and immunogenicity. The review also covers significant progress in lyophilization and cryoprotectant strategies for thermostable formulations, the development of novel delivery platforms like polymer-based nanoparticles, and the evolution of self-amplifying mRNA constructs. Furthermore, it discusses formulation strategies aimed at modulating immune responses, such as tuning reactogenicity and enabling targeted delivery beyond the liver. The authors conclude that these integrated formulation technologies are overcoming key barriers, including cold chain dependency, manufacturing scalability, and therapeutic precision, thereby driving the development of more effective, stable, and accessible next-generation mRNA vaccines for a broader range of infectious diseases and therapeutic applications.
Applications
Regenerative Medicine
We develop glycan-modified hydrogel scaffolds designed to support tissue regeneration. By incorporating specific carbohydrate motifs (such as hyaluronic acid derivatives, sulfated glycosaminoglycan mimetics, or laminin glycopeptides) into tunable polymer networks, we create biomimetic matrices that actively promote stem cell adhesion, proliferation, and lineage-specific differentiation. These synthetic extracellular matrices provide localized biochemical and mechanical signaling, offering a defined platform for organoid culture, 3D bioprinting, and in vivo tissue repair.
Diagnostics and Biosensors
We engineer glycopolymer-functionalized surfaces and particles for highly specific molecular recognition. By immobilizing tailored glycans as capture ligands, we enable the sensitive and selective detection of pathogenic lectins, toxins (e.g., from bacteria or plant sources), and whole pathogens. This technology enhances the performance of diagnostic platforms, including surface plasmon resonance (SPR), quartz crystal microbalance (QCM), and lateral flow assays, for rapid, reliable testing in clinical, point-of-care, and environmental monitoring applications.
Inflammation Management
We design and synthesize multivalent glycopolymers that act as potent, selective inhibitors of cell adhesion molecules. By presenting high-affinity carbohydrate ligands (e.g., sialyl Lewis X mimetics) in a multivalent array, our glycopolymers effectively block the interaction between selectins (E-, P-, and L-selectin) and their endogenous ligands on leukocytes. This inhibits the critical first step of leukocyte rolling and extravasation, providing a targeted therapeutic strategy for acute and chronic inflammatory conditions, including ischemia-reperfusion injury, autoimmune disorders, and metastatic spread.
Drug Delivery Stabilization
We employ glycopolymers as advanced shielding agents to stabilize sensitive therapeutic cargo. By conjugating or complexing with proteins, peptides, or nucleic acids (including mRNA and siRNA), the glycopolymer corona forms a protective hydrophilic shell. This "stealth" layer reduces nonspecific protein adsorption, minimizes recognition by the immune system, and shields the payload from enzymatic degradation. The result is significantly improved pharmacokinetics, reduced immunogenicity, and enhanced delivery efficiency for next-generation biologics.
Advantages
Controlled Architecture
Unlike naturally sourced or enzymatically produced polysaccharides, our synthetic glycopolymers are engineered with precise architectural control. We achieve defined polymer chain lengths and exceptionally low polydispersity (typically Đ < 1.2) through advanced controlled polymerization techniques. This results in a homogeneous macromolecular product, ensuring critical batch-to-batch reproducibility essential for preclinical development and long-term regulatory compliance.
Enhanced Pharmacokinetics
Polymerization provides a strategic advantage by significantly increasing the hydrodynamic volume of the glycan motif. This enlargement reduces the rate of renal filtration and clearance, thereby substantially extending the plasma half-life and systemic exposure of your therapeutic glycan. This tunable property enhances bioavailability, allowing for less frequent dosing and improved efficacy for both diagnostic and therapeutic applications.
Biodegradable Scaffold Options
To address long-term safety and clearance, we provide a selection of biocompatible, enzymatically degradable polymer backbones. Options include poly(ester)-, poly(carbonate)-, or poly(acetal)-based scaffolds that hydrolyze or enzymatically cleave under physiological conditions into benign metabolites. This ensures the polymer vehicle is safely metabolized and eliminated after successfully delivering its glycan payload, mitigating accumulation-related toxicity concerns.
High Grafting Efficiency
Our proprietary polymer activation and coupling chemistry, including specialized activated-ester and other high-yield conjugation platforms, achieves near-quantitative grafting efficiency (>95% conversion). This maximizes the density of the displayed high-value glycan ligands on the polymer scaffold, optimizes the use of often precious carbohydrate materials, and minimizes purification complexity and product loss.
Frequently Asked Questions
Customer Review
"The glyco-polypeptide scaffolds provided by CD BioGlyco were pivotal to our synthetic vaccine platform. Their design, which combined precise antigen presentation with built-in adjuvant properties, elicited a robust and balanced immune response in our animal models. We observed significantly enhanced neutralizing antibody titers and a potent T-cell response, validating the promise of this fully synthetic approach for next-generation vaccine development."
– Dr. P.H., Principal Investigator, Immunology Group
"Utilizing CD BioGlyco's post-polymerization modification service allowed us to seamlessly integrate our own proprietary glycan libraries onto their polymer backbones. The team expertly optimized the conjugation chemistry to achieve the exact grafting density we specified, which was critical for modulating the mechanical properties and bioactivity of our injectable hydrogel. Their service provided the perfect bridge between our glycan discovery and functional material synthesis."
– Senior Researcher, Biomaterials Lab
"CD BioGlyco designed and delivered a custom, star-shaped glycopolymer that served as a highly effective targeting ligand for our LNP formulation. The multivalent architecture dramatically improved the specificity and efficiency of liver cell uptake in vivo, solving a key delivery challenge for our mRNA therapeutic program. Their end-to-end technical support, from molecular design to in vitro validation, was outstanding and instrumental to our project's success."
– Dr. M.K., Director of R&D, Nanomedicine Division
Associated Services
Our polymerization-based glycan modification service utilizes advanced polymerization techniques to create tailored carbohydrate architectures, enabling scalable functionalization. Leveraging this platform, we provide a dedicated HMO Production Service for the synthesis of structurally defined human milk oligosaccharides, including 3'-SL production, 6'-SL production, and lacto-N-triose II production, to support research in nutrition, infant health, and glycobiology.
CD BioGlyco is at the forefront of macromolecular glycobiology. Our Glycan Modification Service empowers you to harness the full potential of multivalency for your therapeutic and diagnostic applications. Contact us!
Reference
Storsberg, J.; et al. Glycopolymers as a tool for specific surface modification of polymeric biomaterials. Biophysica. 2026, 6(2): 23. (Open Access)
For research use only. Not intended for any clinical use.
